Sanofi's Board of Directors has decided not to renew the Paul Hudson’s contract as CEO and to replace him with current Merck CEO Belén Garijo.  They have announced that Olivier Charmeil, Executive Vice President, General Medicines, will assume the role of Interim Chief Executive Officer during the transition.  Garijo has been tasked with strengthening the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!